SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress
Journal of Clinical Investigation · 01.10.2025 · 135 (19)
DOI: 10.1172/jci188933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.10.2025. Verfasst von Hiroshi Maekawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Feinberg Cardiovascular & Renal Research Institute. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Epigenesis, Genetic, Sodium-Glucose Transporter 2, S-Adenosylmethionine. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH/NIDDK, NCI.
Abstract (Originalsprache)
Clinically, blockade of renal glucose resorption by sodium–glucose cotransporter 2 (SGLT2) inhibitors slows progression of kidney disease, yet the underlying mechanisms are not fully understood. We hypothesized that altered renal metabolites underlie observed kidney protection when SGLT2 function is lost. S -adenosylmethionine (SAM) levels were increased in kidneys from mice lacking SGLT2 function on a diabetogenic high-fat diet (SP HFD ) compared with WT mice fed HFD. Elevated SAM in SP HFD was associated with improved kidney function and decreased expression of NF-κB pathway–related genes. Injured proximal tubular cells that emerged under HFD conditions in WT mice and humans consistently showed reduction in expression of the SAM synthetase Mat2a/MAT2A , while MAT2A inhibition, which reduces SAM production, abrogated kidney protection in SP HFD mice. Histone H3 lysine 27 (H3K27) repressive trimethylation of NF-κB–related genes was increased in SP HFD , consistent with SAM’s role as a methyl donor. Our data support a model whereby SGLT2 loss enhances SAM levels within the kidney, leading to epigenetic repression of inflammatory genes and kidney protection under metabolic stress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Feinberg Cardiovascular & Renal Research Institute.
- Division of Nephrology & Hypertension, Department of Medicine.
- Department of Biochemistry and Molecular Genetics, and.
- Simpson Querrey Institute for Epigenetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
- Department of Medicine & Biochemistry and Molecular Genetics, Northwestern University, Chicago, Illinois, USA.
- Department of Medicine, Division of Endocrinology, Metabolism, and Molecular Medicine, and.
Förderung
- NIDDK NIH HHS
- NIH/NIDDK
- NCI
- AHA
- NIH/NEI
Zitieren
APA
Maekawa, H., Zhou, Y., Aoi, Y., Fain, M. E., Kaminski, D. S., Kong, H., Sebo, Z. L., Chakrabarty, R. P., Howard, B. C., Andersen, G., Marcheva, B., Gao, P., Kapitsinou, P., Bass, J., Shilatifard, A., Chandel, N. S., & Quaggin, S. E. (2025). SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. Journal of Clinical Investigation, 135(19). https://doi.org/10.1172/jci188933
Vancouver
Maekawa H, Zhou Y, Aoi Y, Fain ME, Kaminski DS, Kong H, et al. SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. Journal of Clinical Investigation. 2025;135(19). doi:10.1172/jci188933
BibTeX
@article{Maekawa2025,
author = {Maekawa, Hiroshi and Zhou, Yalu and Aoi, Yuki and Fain, Margaret E and Kaminski, Dorian S and Kong, Hyewon and Sebo, Zachary L and Chakrabarty, Ram P and Howard, Benjamin C and Andersen, Grant and Marcheva, Biliana and Gao, Peng and Kapitsinou, Pinelopi and Bass, Joseph and Shilatifard, Ali and Chandel, Navdeep S and Quaggin, Susan E},
title = {SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {19},
doi = {10.1172/jci188933}
}
EUVIMED